In order to access this content you must be logged in and have a subscription to PL Intelligence.
PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
atugen and Sankyo Sign Multi-Year Contract Research Agreement
Sankyo gains rights to cholesterol lowering agent
Sankyo and Fujisawa Agree to Discontinue Business Arrangements on Sankyo's Antifungal CS-758
Biota FLUNET(tm) alliance with Sankyo
Biota secures global influenza partnership with Sankyo
Cygnus, Inc. seeks $450m damages in lawsuit against Sankyo
Cubist licenses antibiotic rights
Cyclacel announces in-licensing of phase I anticancer drug from Sankyo
ArQule and Sankyo extend collaboration
DAIICHI SANKYO AND RANBAXY CONFIRM DEAL IS BINDING AND FINAL ALLAY MARKET RUMOUR AND SPECULATION
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
